Laufen H, Zimmermann T, Yeates R A, Schumacher T, Wildfeuer A
Pfizer Pharmaceutical Group R & D Illertissen, Germany.
Int J Clin Pharmacol Ther. 1999 Jul;37(7):352-60.
The uptake of the antimycotic agent fluconazole in finger and toe nail following various treatment schedules was investigated in order to characterize the pharmacokinetic basis for the systemic treatment of onychomycosis with fluconazole.
Between 8 and 12 healthy, male and female Caucasian subjects were included in four separate studies. Mean age of the subjects in the single studies ranged between 34 years (study 4, group 2; n = 4 male and 4 female) and 38 years (study 4, group 1; n = 4 male and 4 female).
Fluconazole was administered orally over 4 weeks in all studies. The treatment schedules were 150 mg once weekly (study 1), 300 mg once weekly (study 2), 50 mg once daily (study 3) and 150 or 300 mg once weekly in a parallel group study (study 4). At fixed times samples of blood, nail cuttings and nail dust were taken, up to two months after end of treatment. Fluconazole was analyzed in blood plasma and in the nail samples using a highly specific and sensitive gas chromatographic procedure.
High concentrations of fluconazole were found in distal nail clippings with all three treatments. Mean maximum concentrations which occurred in the third or fourth week of treatment amounted to 2.1 microg/g (150 mg/w), 5.4 microg/g (300 mg/w) and 6.5 microg/g (50 mg/d) in finger nails and to 9.6 microg/g (150 mg/w), 12.3 microg/g (300 mg/w) and 12.2 microg/g (50 mg/d) in toe nails. The nail concentrations were 1-2 times (finger) and 2-3 times (toe) higher than the corresponding fluconazole plasma levels and were within the MIC range for dermatophytes and yeasts occurring commonly in onychomycosis. The residence times of fluconazole in the nail plate after the end of treatment was long, with approximate half-lives of 33 days in finger nail and 30 days in toe nail. In pharmacokinetic terms there was no evidence of advantages of the daily dosage (50 mg) over the once-weekly (300 mg) dosage. Fluconazole was found to penetrate into both finger and toe nails at a very fast rate. On the first two days of the 150 mg/w and 300 mg/w treatments, i.e. after the first dosage, fluconazole concentrations in the distal nail plates amounted to 50-80% of the later observed peak levels. The initial concentrations in the upper dorsal plate were particularly high, with mean peak concentrations of 11.9 microg/g (150 mg) and 33.7 microg/g (300 mg) in finger nails and 5.7 microg/g (150 mg) and 24.4 microg/g (300 mg) in toe nails.
Fluconazole is rapidly and highly distributed into finger and foot nail, reaching there higher concentrations than in the plasma. The rapid initial uptake of fluconazole in nail, which is unlike the uptake of other antifungal agents, suggests the existence of special routes of access to the nail for fluconazole, possibly based on high diffusion rates.
研究抗真菌药物氟康唑在不同治疗方案下在手指甲和脚趾甲中的摄取情况,以明确氟康唑全身治疗甲癣的药代动力学基础。
8至12名健康的白种男女受试者被纳入四项独立研究。单项研究中受试者的平均年龄在34岁(研究4,组2;n = 4名男性和4名女性)至38岁(研究4,组1;n = 4名男性和4名女性)之间。
在所有研究中,氟康唑口服给药4周。治疗方案为每周一次150毫克(研究1)、每周一次300毫克(研究2)、每日一次50毫克(研究3)以及在一项平行组研究中每周一次150毫克或300毫克(研究4)。在固定时间采集血液、指甲剪和指甲屑样本,直至治疗结束后两个月。使用高特异性和高灵敏度的气相色谱法分析血浆和指甲样本中的氟康唑。
所有三种治疗方案下,在远端指甲剪中均发现高浓度的氟康唑。治疗第三或第四周出现的平均最大浓度在手指甲中分别为2.1微克/克(150毫克/周)、5.4微克/克(300毫克/周)和6.5微克/克(50毫克/天),在脚趾甲中分别为9.6微克/克(150毫克/周)、12.3微克/克(300毫克/周)和12.2微克/克(50毫克/天)。指甲浓度比相应的氟康唑血浆水平高1至2倍(手指)和2至3倍(脚趾),且处于甲癣中常见皮肤癣菌和酵母菌的最低抑菌浓度范围内。治疗结束后,氟康唑在指甲板中的停留时间很长,手指甲中的半衰期约为33天,脚趾甲中的半衰期约为30天。从药代动力学角度来看,没有证据表明每日剂量(50毫克)优于每周剂量(300毫克)。发现氟康唑以非常快的速度渗透到手指甲和脚趾甲中。在150毫克/周和300毫克/周治疗的头两天,即首次给药后,远端指甲板中的氟康唑浓度达到后期观察到的峰值水平的50 - 80%。上背侧指甲板中的初始浓度特别高,手指甲中的平均峰值浓度分别为11.9微克/克(150毫克)和33.7微克/克(300毫克),脚趾甲中的平均峰值浓度分别为5.7微克/克(150毫克)和24.4微克/克(300毫克)。
氟康唑能迅速且大量分布到手指甲和脚趾甲中,在那里达到比血浆中更高的浓度。氟康唑在指甲中的快速初始摄取与其他抗真菌药物不同,这表明氟康唑可能存在特殊的进入指甲的途径,可能基于高扩散率。